{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:42:24Z","timestamp":1784626944342,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T08:51:49Z","timestamp":1697791909000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"24","author":[{"given":"Andrew J.","family":"Klink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Brokars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-9994","authenticated-orcid":false,"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.005_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2023.10.005_bib0002","unstructured":"NIH National Cancer Institute. Cancer Stat Facts: Leukemia \u2013 chronic myeloid leukemia (CML). https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html. Accessed March 2, 2023."},{"key":"10.1016\/j.clml.2023.10.005_bib0003","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.10.005_bib0004","series-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8-Year Follow Up: Sustained Survival and Low Risk for Progression or Events in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Imatinib","author":"Deininger","year":"2009"},{"key":"10.1016\/j.clml.2023.10.005_bib0005","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0006","unstructured":"Novartis Pharmaceuticals. Gleevec (Imatinib). East Hanover, NJ; Novartis Pharmaceuticals, Inc. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/gleevec_tabs.pdf. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0007","unstructured":"Novartis Pharmaceuticals. Tasigna (Nilotinib). East Hanover, NJ; Novartis Pharmaceuticals, Inc. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/tasigna.pdf. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0008","unstructured":"Sprycel. Sprycel (Dasatinib) Summary of Product Characteristics. Dublin, Ireland; Bristol-Myers Squibb. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sprycel-epar-product-information_en.pdf. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0009","unstructured":"Pfizer Inc. Bosulif (Bosutinib). New York, NY; Pfizer Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203341lbl.pdf. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1179\/1607845413Y.0000000119","article-title":"BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia","volume":"19","author":"Khan","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2023.10.005_bib0011","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/17474086.2013.835697","article-title":"The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment","volume":"6","author":"Jain","year":"2013","journal-title":"Exp Rev Hematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0012","first-page":"1006","article-title":"Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment","volume":"20","author":"Trivedi","year":"2014","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clml.2023.10.005_bib0013","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jval.2013.07.004","article-title":"Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence","volume":"16","author":"Oriana","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2023.10.005_bib0014","unstructured":"NIH National Cancer Institute. Dasatinib. https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/dasatinib. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0015","unstructured":"U.S. Food and Drug Administration. FDA approves dasatinib for pediatric patients with CML. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-dasatinib-pediatric-patients-cml. Accessed August 8, 2022."},{"key":"10.1016\/j.clml.2023.10.005_bib0016","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.005_bib0017","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.005_bib0018","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2023.10.005_bib0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.005_sbref0020","series-title":"Referenced With Permission From the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7) for Chronic Myeloid Leukemia Version 1.2023","year":"2023"},{"key":"10.1016\/j.clml.2023.10.005_bib0021","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.10.005_bib0022","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/bloodadvances.2018018614","article-title":"Imatinib is still recommended for frontline therapy for CML","volume":"2","author":"Hantel","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.10.005_bib0023","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.canlet.2012.12.018","article-title":"Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib","volume":"333","author":"Breccia","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2023.10.005_bib0024","first-page":"1494","article-title":"Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients","volume":"26","author":"Rivera","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2023.10.005_bib0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/14656566.2019.1599357","article-title":"What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly?","volume":"20","author":"Shallis","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2023.10.005_bib0026","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2023.10.005_bib0027","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.005_bib0028","unstructured":"U.S. Food and Drug Administration. Dasatinib. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021986s025lbl.pdf. Accessed September 7, 2023."},{"key":"10.1016\/j.clml.2023.10.005_bib0029","series-title":"Sprycel (Dasatinib) prescribing information","year":"2021"},{"key":"10.1016\/j.clml.2023.10.005_bib0030","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/s41375-020-0805-1","article-title":"Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study","volume":"34","author":"Cortes","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.10.005_bib0031","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0032","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-016-2839-z","article-title":"Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response","volume":"96","author":"Cervantes","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0033","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/j.clml.2021.01.020","article-title":"Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia","volume":"21","author":"Shin","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.10.005_bib0034","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50\u2009mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.10.005_bib0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.10.005_bib0036","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50 mg\/day versus standard-dose dasatinib 100 mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0037","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0038","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ejh.12423","article-title":"Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (N ord CML 006)","volume":"94","author":"Hjorth-Hansen","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.10.005_bib0039","series-title":"Spirit 2: an NCRI Randomised Study Comparing Dasatinib With Imatinib in Patients With Newly Diagnosed CML","author":"O'Brien","year":"2014"},{"key":"10.1016\/j.clml.2023.10.005_bib0040","first-page":"611","article-title":"NCCN guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia","volume":"17","author":"Shah","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2023.10.005_bib0041","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T20:56:01Z","timestamp":1709240161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021493"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}